Entecavir for the treatment of chronic hepatitis B infection.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 31-36

  Shepherd, J ^a   Gospodarevskaya, E ^b   Frampton, G ^b   Cooper, K ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; ENTECAVIR; GUANINE;

ADULT; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS B; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84886943068     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/05     Document Type: Review

References (1)